Fefol Spansule Capsules
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Fefol Spansule Capsules
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Dried ferrous sulphate 150mg (equivalent to 47mg elemental iron)
Folic Acid BP 500 micrograms
3 PHARMACEUTICAL FORM
Spansule Capsules.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Fefol is a haematinic preparation for prophylaxis of iron and folic acid deficiency during pregnancy.
4.2 Posology and method of administration
Dosage
Adults only: one capsule a day during pregnancy. Some pregnant patients may need a higher dose of iron because of dietary or other factors.
Children and elderly not recommended.
Method of administration
Oral
4.3 Contraindications
Do not use in patients hypersensitive to the product or those with iron overload.
4.4 Special warnings and precautions for use
The label will state
"Important warning: Contains Iron. Keep out of reach and sight of children, as overdose may be fatal"
This will appear on the front of the pack within a rectangle in which there is no other information.
Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia.
Failure to respond to treatment may indicate other causes of anaemia and should be further investigated.
The folic acid content is unlikely to mask pernicious anaemia should this condition be present; pregnancy during pernicious anaemia is very rare.
4.5 Interaction with other medicinal products and other forms of interaction
Iron chelates with tetracyclines and absorption of both agents may be impaired.
Absorption of iron may be impaired by penicillamine and by antacids. Such potential interactions can be reduced by separating administration of each product by several hours.
4.6 Fertility, Pregnancy and lactation
"Fefol” should not be used during the first trimester of pregnancy. Prophylaxis of iron and folate deficiency during the remainder of pregnancy is justified.
4.7 Effects on ability to drive and use machines
None.
4.8 Undesirable effects
Dark stools are usual during iron therapy, and nausea and other symptoms of gastrointestinal irritation, such as anorexia, vomiting, discomfort, constipation, and diarrhoea are sometimes encountered. "Fefol Spansule" Capsules are designed to reduce the possibility of gastrointestinal irritation. There have been rare reports of allergic reactions.
4.9 Overdose
Iron overdosage is dangerous, particularly in children and requires immediate attention. Treatment is necessary if more than 30mg elemental iron per kilogram of body weight has been ingested. In the first phase, 30 minutes to 6 hours after ingestion, symptoms may include abdominal pain, vomiting, diarrhoea and haematemesis, with in more severe cases, coma, convulsions and shock. Symptoms then abate, with either recovery, or within 12 hours after ingestion, deterioration. Symptoms can then include severe lethargy or coma, gastrointestinal haemorrhage, severe shock, metabolic acidosis, convulsions, jaundice, coagulation disorders, hypoglycaemia, renal failure and pulmonary oedema. These may last up to 48 hours after ingestion. In the last phase, 2 to 5 weeks after ingestion effects such as encephalopathy, hepatic necrosis and pyloric stenosis may occur. The sustained-release "spansule" capsule presentation of ferrous sulphate may delay excessive absorption of iron and allow more time for initiation of appropriate countermeasures. Gastric lavage should be carried out in the early stages, or if this is not possible, vomiting should be induced. Give oral desferrioxamine (2g for a child and 5g for an adult) and demulcents. If serum iron levels at 4 hours or more post-ingestion are over 5mg/l in a child, or 8mg/l in an adult, or if the patient is in shock or coma, intramuscular or intravenous desferrioxamine should be used according to instructions for this product. Symptomatic and supportive measures should be given as required.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
The product is an oral iron and folic acid preparation for the prophylaxis of iron and folic acid deficiency during pregnancy.
5.2 Pharmacokinetic properties
The product is formulated to release iron over a period of several hours in the small intestine where absorption is greater rather than in the stomach where gastric irritation may be caused. The folic acid is available immediately.
5.3 Preclinical safety data
No further information.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Maize Starch EP Talc EP
Kaolin Heavy EP Sucrose EP Gelatin BP
Titanium Dioxide (E171)
Red Iron Oxide (E172)
Povidone 30 BP
Glyceryl monostearate HSE
White beeswax USP
Calcium Sulphate Dihydrate HSE
Quinoline Yellow (EI04)
Patent Blue V (E13l)
Gelatin BP
6.2 Incompatibilities
None.
6.3 Shelf life
60 months (all pack sizes).
6.4 Special precautions for storage
Store in a dry place at a temperature not exceeding 25°C and protect from light.
6.5 Nature and contents of container
Standard Securitainers in packs of 250 capsules.
Blister packs of PVC/aluminium foil (with secondary perforated paper layer) of 15 and 30 capsules.
7
MARKETING AUTHORISATION HOLDER
Henley Laboratories Limited
The Station House
Station Road
Whalley
Clitheroe
BB7 9RT
United Kingdom
8
9
10
19/01/2016